Core Insights - The article highlights Abbott's innovative iCGM technology, which represents a significant advancement in diabetes management, transitioning from mere monitoring to comprehensive management of blood glucose levels [1][2][4]. Product Innovation - Abbott showcased its new iCGM products, including the Libre Select and FreeStyle Libre 2 Plus sensors, at the China International Import Expo, emphasizing their compatibility with insulin pumps and clinical decision support [1][3]. - The iCGM technology is positioned as a non-auxiliary tool that directly informs diabetes treatment decisions, marking a critical evolution in the industry [2]. Clinical Impact - The introduction of iCGM is expected to enhance patient experience by providing continuous and trend-based data, shifting the perception of blood glucose monitoring from a burdensome task to a seamless part of daily life [4][5]. - iCGM also improves clinical efficiency for healthcare providers, allowing for easier access to continuous data and better communication with patients regarding treatment adjustments [5]. Market Strategy - Abbott is deepening its market presence in China through strategic partnerships, such as with WeDoctor, to create a comprehensive digital diabetes management system [6]. - The company aims to make advanced diabetes management technologies more accessible to patients, with a focus on localizing its iCGM digital connectivity capabilities [6]. Future Outlook - The article notes the challenges Abbott faces, including cost reduction, increasing insurance coverage, and educating healthcare providers and patients in grassroots markets [7]. - The significance of Abbott's high-standard technology and industry collaboration extends beyond commercial value, contributing to improved quality of life and aligning with China's "Healthy China 2030" strategic vision [7].